ES2083989T3 - Proteina modificada con glucosaminoglucano, procedimiento para la produccion de dicha proteina, utilizacion y composicion farmaceutica que la contiene - Google Patents

Proteina modificada con glucosaminoglucano, procedimiento para la produccion de dicha proteina, utilizacion y composicion farmaceutica que la contiene

Info

Publication number
ES2083989T3
ES2083989T3 ES90119607T ES90119607T ES2083989T3 ES 2083989 T3 ES2083989 T3 ES 2083989T3 ES 90119607 T ES90119607 T ES 90119607T ES 90119607 T ES90119607 T ES 90119607T ES 2083989 T3 ES2083989 T3 ES 2083989T3
Authority
ES
Spain
Prior art keywords
protein
glucosaminoglucan
procedure
production
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90119607T
Other languages
English (en)
Inventor
Katsukiyo Sakurai
Kyosuke Miyazaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seikagaku Corp
Original Assignee
Seikagaku Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seikagaku Corp filed Critical Seikagaku Corp
Application granted granted Critical
Publication of ES2083989T3 publication Critical patent/ES2083989T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

UNA PROTEINA MODIFICADA GLICOSAMINOGLICANA DONDE UN GRUPO AMINO DE UNA PROTEINA ESTA UNIDO A UN GRUPO ALDEHIDO, QUE HA SIDO FORMADO AL REDUCIR Y OXIDAR PARCIALMENTE LA MITAD DEL AZUCAR TERMINAL REDUCTOR DE UNA GLICOSAMINOGLICANA, QUE TIENE UNA GRAN ESTABILIDAD EN VIVO Y PUEDE RETENER ACTIVIDAD FISIOLOGICA DE LA PROTEINA DURANTE UN PERIODO DE TIEMPO PROLONGADO.
ES90119607T 1990-03-30 1990-10-12 Proteina modificada con glucosaminoglucano, procedimiento para la produccion de dicha proteina, utilizacion y composicion farmaceutica que la contiene Expired - Lifetime ES2083989T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2081163A JP2975632B2 (ja) 1990-03-30 1990-03-30 グリコサミノグリカン修飾プロテイン

Publications (1)

Publication Number Publication Date
ES2083989T3 true ES2083989T3 (es) 1996-05-01

Family

ID=13738789

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90119607T Expired - Lifetime ES2083989T3 (es) 1990-03-30 1990-10-12 Proteina modificada con glucosaminoglucano, procedimiento para la produccion de dicha proteina, utilizacion y composicion farmaceutica que la contiene

Country Status (12)

Country Link
US (1) US5310881A (es)
EP (1) EP0454898B1 (es)
JP (1) JP2975632B2 (es)
KR (1) KR100188382B1 (es)
AT (1) ATE135375T1 (es)
AU (1) AU649416B2 (es)
CA (1) CA2027447A1 (es)
DE (1) DE69025920T2 (es)
DK (1) DK0454898T3 (es)
ES (1) ES2083989T3 (es)
FI (1) FI102836B1 (es)
NO (1) NO179044C (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0502550B1 (en) * 1991-03-07 1995-01-04 Mect Corporation Colominic acid and partial hydrolysis products of colominic acid for the preparation of medicaments for the treatment of hepatitis, nephritis and arthritis
US5846951A (en) * 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
GB9112212D0 (en) * 1991-06-06 1991-07-24 Gregoriadis Gregory Pharmaceutical compositions
GB2266239B (en) * 1992-03-25 1996-03-06 Jevco Ltd Wound healing compositions containing chondroitin sulphate oligosaccharides
CA2091544A1 (en) * 1992-03-26 1993-09-27 Shing F. Kwan Stabilization of functional proteins
AU711535B2 (en) * 1994-02-23 1999-10-14 Kyowa Hakko Kirin Co., Ltd. Platelet growth accelerator
JPH09503001A (ja) * 1994-05-09 1997-03-25 ベーリンガー マンハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング ニューロンを保護するためのコンドロイチン硫酸プロテオグリカンの使用
US6228998B1 (en) 1994-07-22 2001-05-08 Seikagaku Kogyo Kabushiki Kaisha Amino spacered glycosaminoglycan derivatives and their use in copolymerization with acrylamide
US5912000A (en) * 1994-09-23 1999-06-15 Zonagen, Inc. Chitosan induced immunopotentiation
ATE223235T1 (de) * 1994-09-23 2002-09-15 Zonagen Inc Chitosan induzierte verstärkung
US5677276A (en) * 1994-12-23 1997-10-14 La Jolla Cancer Research Foundation Immobilization of peptides to hyaluronate
CA2232527C (en) * 1995-09-19 2008-09-02 Seikagaku Corporation Anti-inflammatory agent
US6562781B1 (en) 1995-11-30 2003-05-13 Hamilton Civic Hospitals Research Development Inc. Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US7045585B2 (en) * 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
US6491965B1 (en) 1995-11-30 2002-12-10 Hamilton Civic Hospitals Research Development, Inc. Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
JP2001502052A (ja) * 1996-09-25 2001-02-13 ユニバーサル ヘルスウォッチ，インコーポレーテッド 液体移動および干渉に対する抵抗を改良した診断用検査デバイス
WO2001005434A2 (en) * 1999-07-20 2001-01-25 Amgen Inc. Hyaluronic acid-protein conjugates
EP2292271A3 (en) * 2001-10-10 2011-09-14 BioGeneriX AG Remodelling and glycoconjugation of an antibody
ZA200700168B (en) * 2001-10-10 2010-02-24 Novo Nordisk As Remodeling and glycoconjugation of peptides
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
JP2006516534A (ja) 2002-09-11 2006-07-06 フレセニウス・カビ・ドイッチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｈａｓ化ポリペプチド、特にｈａｓ化エリスロポエチン
CA2499872C (en) * 2002-09-25 2015-11-17 Johns Hopkins University School Of Medicine Cross-linked polymer matrices, and methods of making and using same
US8673333B2 (en) * 2002-09-25 2014-03-18 The Johns Hopkins University Cross-linked polymer matrices, and methods of making and using same
US7862831B2 (en) * 2002-10-09 2011-01-04 Synthasome, Inc. Method and material for enhanced tissue-biomaterial integration
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
JP4566194B2 (ja) 2003-08-12 2010-10-20 リポクセン テクノロジーズ リミテッド タンパク質の誘導体化及び結合のためのシアル酸誘導体
WO2006089119A2 (en) * 2005-02-18 2006-08-24 Cartilix, Inc. Biological adhesive
EP3138855A1 (en) 2005-02-23 2017-03-08 Lipoxen Technologies Limited Activated sialic acid derivatives for protein derivatisation and conjugation
EP1886696A1 (en) * 2006-08-03 2008-02-13 Endotis Pharma Conjugates of antithrombin binding oligosaccharide derivatives and therapeutic proteins
US8658593B2 (en) 2011-06-06 2014-02-25 The Cleveland Clinic Foundation Treatment of extracellular matrix to reduce inflammation
WO2015046602A1 (ja) 2013-09-30 2015-04-02 生化学工業株式会社 タンパク質の血中滞留性の増強方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2824092A (en) * 1955-01-04 1958-02-18 Robert E Thompson Process of preparation of a gelatincarboxymethyl cellulose complex
GB1479268A (en) * 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
US4301153A (en) * 1977-03-21 1981-11-17 Riker Laboratories, Inc. Heparin preparation
CA1171375A (en) * 1980-09-15 1984-07-24 Ulf P.F. Lindahl Oligosaccharides having selective anticoagulation activity
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4526714A (en) * 1982-12-13 1985-07-02 Cordis Europa N.V. Conjugates of anticoagulant and protein
NL188622C (nl) * 1981-12-15 1992-08-17 Cordis Europ Werkwijze ter verbetering van de bloedcompatibiliteit van een materiaaloppervlak door bekleding daarvan met een heparine of heparine-analoga en een eiwit houdende film, alsmede voorwerp, omvattende een oppervlak met verbeterde bloedcompatibiliteit verkregen onder toepassing van een op het oppervlak aangebrachte heparine of heparine-analoga en een eiwit houdende film.
SE8200751L (sv) * 1982-02-09 1983-08-10 Olle Larm Forfarande for kovalent koppling for framstellning av konjugat och hervid erhallna produkter
US4585754A (en) * 1984-01-09 1986-04-29 Valcor Scientific, Ltd. Stabilization of proteins and peptides by chemical binding with chondroitin
EP0242416B1 (en) * 1986-04-22 1991-07-24 Valcor Scientific, Ltd. Method of protein stabilization
US4863907A (en) * 1984-06-29 1989-09-05 Seikagaku Kogyo Co., Ltd. Crosslinked glycosaminoglycans and their use
US4745180A (en) * 1986-06-27 1988-05-17 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using heparin fragments
DE3636590A1 (de) * 1986-10-28 1988-05-26 Braun Melsungen Ag Blutersatzmittel
FR2631970B1 (fr) * 1988-05-24 1993-12-24 Sanofi N-polyosyl-polypeptides
DE3819079A1 (de) * 1988-06-04 1989-12-07 Hoechst Ag Hirudin-derivate mit verzoegerter wirkung
WO1990001332A1 (en) * 1988-08-10 1990-02-22 Cetus Corporation Plasminogen activator-heparin conjugates

Also Published As

Publication number Publication date
NO904378L (no) 1991-10-01
DK0454898T3 (da) 1996-04-15
KR910016770A (ko) 1991-11-05
EP0454898B1 (en) 1996-03-13
FI102836B (fi) 1999-02-26
FI102836B1 (fi) 1999-02-26
FI905003A (fi) 1991-10-01
KR100188382B1 (ko) 1999-06-01
EP0454898A1 (en) 1991-11-06
CA2027447A1 (en) 1991-10-01
NO179044C (no) 1996-07-24
AU649416B2 (en) 1994-05-26
JPH03284698A (ja) 1991-12-16
US5310881A (en) 1994-05-10
ATE135375T1 (de) 1996-03-15
AU6450690A (en) 1991-10-31
DE69025920T2 (de) 1996-08-14
JP2975632B2 (ja) 1999-11-10
DE69025920D1 (de) 1996-04-18
NO904378D0 (no) 1990-10-10
NO179044B (no) 1996-04-15
FI905003A0 (fi) 1990-10-11

Similar Documents

Publication Publication Date Title
ES2083989T3 (es) Proteina modificada con glucosaminoglucano, procedimiento para la produccion de dicha proteina, utilizacion y composicion farmaceutica que la contiene
DE3867683D1 (de) Dosierspritze.
EA199900325A1 (ru) Форма d дигидрата оланзапина
EA199800946A1 (ru) Концентрированный препарат антител
NO891663L (no) Sjampo med lav ph som inneholder climbazol.
FI946004A0 (fi) Lääketieteellisessä toimenpiteessä käytettävä trombiiniverifraktio
EA200000920A1 (ru) Производные бициклических гидроксамовых кислот
GR82243B (es)
DK644388D0 (da) Farmaceutiske praeparater indeholdende 3-hydroxy-smoeresyrederivater
MX18879A (es) Analogos de la prostaglandina de amida heterociclica substituida con 7-oxabicicloheptilo.
SV1998000139A (es) Procedimiento para la preparacion de acidos 8-metoxi-quinoloncarboxilicos ref.lea 32634-sv
UA32523C2 (uk) Пептиди, які мають високу біологічну активність, та фармацевтична композиція на їх основі
ES2106031T3 (es) Una composicion comprendiendo un factor de crecimiento, su metodo de obtencion y uso.
DK69685A (da) Oralt praeparat, der indeholder allergen
PT90661A (pt) Processo para a preparacao de composicoes farmaceuticas contendo inibidores da enzima conversora de angiotensina e moduladores de canal de potassio
ES2003075A4 (es) Sintesis de peptidos en fase solida.
ES2058771T3 (es) Preparado combinado con efecto antitrombotico.
SV1996000062A (es) Mejora de la tolerancia de beta-aminoacidos farmaceuticamente activos ref. lea 31175-sv
IT8721687A0 (it) Derivati dell'ossima della 1,2,5,6-tetraidropiridin-3-carbossa ldeide, loro procedimento di preparazione e loro impiego come sostanze medicinali.
DK183582A (da) Fremgangsmaade til fremstilling af oxazolderivater
IL87561A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
ES2017900T3 (es) Derivados del acido tiazolidin-4-carboxilico, su preparacion y composiciones farmaceuticas que lo contienen.
NO880325L (no) Fremgangsmaate for fremstilling av n,n-(dibenzoheksatrienylen)ureaer.
DK427589A (da) Lagerstabil vandig oploesning af alkyltrialkoxysilaner
CS954785A2 (en) Zpusob pripravy derivatu n substituovane aziridin2 karboxylove kyseliny

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 454898

Country of ref document: ES